BiotechTube

SUNPG18_07 I (Tildrakizumab 200 mg) + SUNPG18_07 II (Tildrakizumab 100 mg)

Phase 2/3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
65
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psoriatic Arthritis

Conditions

Psoriatic Arthritis

Trial Timeline

Jul 11, 2018 โ†’ Sep 18, 2023

NCT ID
NCT03552276

About SUNPG18_07 I (Tildrakizumab 200 mg) + SUNPG18_07 II (Tildrakizumab 100 mg)

SUNPG18_07 I (Tildrakizumab 200 mg) + SUNPG18_07 II (Tildrakizumab 100 mg) is a phase 2/3 stage product being developed by Sun Pharmaceutical for Psoriatic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03552276. Target conditions include Psoriatic Arthritis.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT03552276Phase 2/3Completed

Competing Products

20 competing products in Psoriatic Arthritis

See all competitors
ProductCompanyStageHype Score
SonelokimabMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab + Placebo + AdalimumabMoonLake ImmunotherapeuticsPhase 2
47
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab + Placebo + RisankizumabMoonLake ImmunotherapeuticsPhase 3
72
Dose A VTX958 + Dose B VTX958 + PlaceboVentyx BiosciencesPhase 2
47
Ixekizumab + PlaceboEli LillyPhase 3
77
Ixekizumab + TirzepatideEli LillyPre-clinical
23
Ixekizumab + TirzepatideEli LillyPhase 3
77
Ixekizumab + AdalimumabEli LillyApproved
85
Alefacept + Methotrexate + PlaceboAstellas PharmaPhase 2
52
TILD sub-cutaneous (SC) injectionSun PharmaceuticalPhase 3
77
SUNPG1623 I + SUNPG1623 II + SUNPG1623 III + SUNPG1623 IV + PLACEBOSun PharmaceuticalPhase 2
52
TILD + matching placebo injectionsSun PharmaceuticalPhase 3
77
TILD + matching placebo injectionsSun PharmaceuticalPhase 3
77
Ixekizumab + AdalimumabEli LillyPhase 3
77
TirzepatideEli LillyApproved
85
Placebo + Ixekizumab 80 mg Q4W + Ixekizumab 80 mg Q2WEli LillyPhase 3
77
GuselkumabJohnson & JohnsonApproved
85
RSS0393 ointment + RSS0393 ointment + RSS0393 ointment placeboJiangsu Hengrui MedicinePhase 2
52
SHR0302 tabletsใ€Placebo + SHR0302 tabletsใ€Placebo + PlaceboJiangsu Hengrui MedicinePhase 3
77

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85